Pacira BioSciences (PCRX) Deferred Taxes (2020 - 2026)

Pacira BioSciences' Deferred Taxes history runs 7 years deep, the most recent figure standing at $1.7 million for Q1 2026.

• On a quarterly basis, Deferred Taxes rose 23.84% year-over-year to $1.7 million in Q1 2026; TTM through Mar 2026 was $6.8 million, a 63.3% decrease from a year earlier, with the FY2025 full-year figure at $6.5 million, down 68.59% from the prior year.
• Deferred Taxes improved to $1.7 million in Q1 2026 per PCRX's latest filing, from -$3.7 million in the prior quarter.
• Across five years, Deferred Taxes topped out at $12.5 million in Q2 2024 and bottomed at -$10.8 million in Q4 2022.
• The 5-year median for Deferred Taxes is $1.7 million (2026), against an average of $2.1 million.
• Across the five-year window, Deferred Taxes slumped 25417.24% in 2023 and jumped 623.95% in 2025, its largest moves.
• Year by year, Deferred Taxes stood at -$10.8 million in 2022, then jumped by 160.89% to $6.6 million in 2023, then sank by 46.86% to $3.5 million in 2024, then slumped by 206.73% to -$3.7 million in 2025, then surged by 146.21% to $1.7 million in 2026.
• Per Business Quant, the three latest PCRX Deferred Taxes figures stand at $1.7 million (Q1 2026), -$3.7 million (Q4 2025), and $8.1 million (Q3 2025).